Edition:
United States

Tonix Pharmaceuticals Holding Corp (TNXP.OQ)

TNXP.OQ on NASDAQ Stock Exchange Global Market

4.41USD
15 Jun 2018
Change (% chg)

$0.47 (+11.93%)
Prev Close
$3.94
Open
$3.90
Day's High
$4.41
Day's Low
$3.90
Volume
31,086
Avg. Vol
13,438
52-wk High
$5.10
52-wk Low
$2.72

Select another date:

Thu, May 17 2018

BRIEF-Tonix Pharmaceuticals Holding Corp Enters Into Sales Agreement With Cowen And Co

* TONIX PHARMACEUTICALS HOLDING CORP SAYS ON MAY 1, CO ENTERED INTO SALES AGREEMENT WITH COWEN AND CO RELATING TO SHARES OF CO'S COMMON STOCK OFFERED

BRIEF-Tonix Pharmaceuticals Posts Q1 Loss Of $0.88 Per Share

* TONIX PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES PROGRAMS UPDATE

BRIEF-Tonix Pharmaceuticals Holding Qtrly Net Loss Per Common Share $0.88

* TONIX PHARMACEUTICALS HOLDING CORP QTRLY NET LOSS PER COMMON SHARE $0.88 Source text: (https://bit.ly/2G8HkXY) Further company coverage:

BRIEF-Tonix Pharmaceuticals Holding Says Files For Mixed Shelf Of Up To $75 Mln

* TONIX PHARMACEUTICALS HOLDING SAYS FILES FOR MIXED SHELF OF UP TO $75 MILLION - SEC FILING Source text for Eikon: (http://bit.ly/2KqLRZ4) Further company coverage:

BRIEF-Tonix Pharmaceuticals Receives IND Clearance By U.S. FDA For TNX-102 SL

* TONIX PHARMACEUTICALS RECEIVES IND CLEARANCE BY U.S. FDA FOR TNX-102 SL IN AGITATION IN ALZHEIMER’S DISEASE Source text for Eikon: Further company coverage:

BRIEF-Tonix Pharma Ready To File For Approval Of PTSD Treatment In 2019 Based On Study Data

* TONIX PHARMACEUTICALS ACHIEVES 50 PERCENT ENROLLMENT IN PHASE 3 TRIAL OF FDA-DESIGNATED BREAKTHROUGH THERAPY TONMYA® (CYCLOBENZAPRINE HCL SUBLINGUAL TABLETS) FOR THE TREATMENT OF PTSD

BRIEF-Tonix Pharma Reports Q4 Loss Per Share $0.71

* TONIX PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES PROGRAMS UPDATE

BRIEF-Baker Bros Advisors LP Reports 8.9 Pct Passive Stake In Tonix Pharmaceuticals Holding As Of Dec 31, 2017 - SEC Filing

* BAKER BROS ADVISORS LP REPORTS 8.9 PERCENT PASSIVE STAKE IN TONIX PHARMACEUTICALS HOLDING AS OF DEC 31, 2017 - SEC FILING Source text: (http://bit.ly/2HcDj6B) Further company coverage:

BRIEF-Tonix Pharmaceuticals Receives Notice Of Allowance For New U.S. Patent For The Active Ingredient In Tonmya

* TONIX PHARMACEUTICALS RECEIVES NOTICE OF ALLOWANCE FOR NEW U.S. PATENT FOR THE ACTIVE INGREDIENT IN TONMYA (CYCLOBENZAPRINE HCL SUBLINGUAL TABLETS) Source text for Eikon: Further company coverage:

Select another date: